GlassScriptPhysician profile
David J Vinci
NPI 1952300824
$2,742.59
in general payments reported to CMS, 2019-2025
22 companies · $752 in 2025
The $752 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $135 · 2021: $361 · 2022: $280 · 2023: $576 · 2024: $495 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $825.54 | 2019-2025 | Precision 1, Tryptyr, Rocklatan |
| Bausch & Lomb Americas INC. | $486.44 | 2022-2025 | Miebo, Vyzulta, Infuse |
| Biotissue Holdings INC. | $171.22 | 2019-2024 | |
| Coopervision INC. | $160.23 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.39 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $131.21 | 2024-2025 | Xdemvy |
| Amgen INC. | $124.89 | 2024 | Tepezza |
| Optos, INC. | $82.83 | 2021 | |
| Sight Sciences, INC. | $81.77 | 2020-2021 | |
| Oyster Point Pharma, INC. | $70.82 | 2025 | Ryzumvi, Tyrvaya |
| Allergan, INC. | $60.31 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $59.78 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $52.39 | 2019-2022 | |
| Horizon Therapeutics Plc | $48.95 | 2023 | Tepezza |
| Visioneering Technologies, INC. | $47.63 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $42.42 | 2024-2025 | Contact Lens, Spectacle Lenses |
| Sun Pharmaceutical Industries INC. | $34.60 | 2019-2025 | |
| Harrow Eye, LLC | $33.05 | 2024 | Vevye |
| Abbvie INC. | $27.21 | 2024 | |
| Aerie Pharmaceuticals, INC. | $21.50 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.32 | 2022 | |
| Dompe US, INC. | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vinci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.